Second generation monoclonal antibodies having binding specificity to TAG-72 and human carcinomas and methods for employing the same

US5512443A · kind A · utility

Assignee

• The United States of America, as represented by the Department of Health and Human Services · US

Inventors

• Jeffrey Schlom · Potomac, US
• David Colcher · Potomac, US

Key dates

• Filing date: Jul 2, 1990
• Grant date: Apr 30, 1996
• Expiry date: Jul 2, 2010

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S436/813
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to second generation monoclonal antibodies having binding specificity to a tumor associated glycoprotein having an approximate molecular weight of >10.sup.6 d ("TAG-72") and human carcinomas and methods for employing the same. Hybridomas producing such antibodies have been prepared.